In conclusion, our findings suggest that the immune checkpoint LAG3 is closely associated with immune activation in the ESCC tumor microenvironment in terms of both overall content and spatial relationship and may serve as a potential predictor of overall survival and CCRT efficacy in ESCC patients. This evidence concerns the gene LAG3 and esophageal squamous cell carcinoma.